For the better part of a year, Scholar Rock has worked behind the scenes mapping out an approach to hit well-known disease targets in an unusual way. Now, the nascent Cambridge, MA-based startup is ready to discuss what it’s found. Scholar Rock is emerging from stealth mode today to make two announcements: First, it’s licensed intellectual property from Boston Children’s Hospital related to what it calls “niche” activators—the new drug candidates it wants to develop against certain types of growth factors.
Help employers find you! Check out all the jobs and post your resume.
